What is the recommended dosage of Strattera (atomoxetine) for children, adolescents, and adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Strattera (Atomoxetine) Dosing

Strattera dosing differs based on body weight: children and adolescents under 70 kg start at 0.5 mg/kg/day and titrate to 1.2 mg/kg/day, while those over 70 kg and adults start at 40 mg/day and titrate to 80 mg/day. 1

Children and Adolescents Under 70 kg

Initial Dosing:

  • Start at approximately 0.5 mg/kg/day total daily dose 1
  • For children weighing less than 25 kg, single doses should not exceed 15 mg 2
  • Wait a minimum of 3 days before increasing the dose 1

Target Dosing:

  • Increase to 1.2 mg/kg/day as the target dose 1
  • Can be given as a single morning dose OR divided into morning and late afternoon/early evening doses 1
  • Maximum daily dose: 1.4 mg/kg or 100 mg, whichever is less 1
  • No additional benefit demonstrated for doses higher than 1.2 mg/kg/day 1

Children and Adolescents Over 70 kg and Adults

Initial Dosing:

  • Start at 40 mg/day total daily dose 1
  • Wait a minimum of 3 days before increasing 1

Target Dosing:

  • Increase to 80 mg/day as the target dose 1
  • Can be given as a single morning dose OR divided into morning and late afternoon/early evening doses 1
  • After 2-4 additional weeks at 80 mg/day, may increase to maximum of 100 mg/day if optimal response not achieved 1
  • The typical titration pattern is to adjust every 7-14 days from 40 mg to 60 mg, then to 80 mg/day 2
  • Maximum recommended dose: 100 mg/day 1

Special Populations Requiring Dose Adjustment

Hepatic Impairment:

  • Moderate hepatic insufficiency (Child-Pugh Class B): Reduce initial and target doses to 50% of normal dose 1
  • Severe hepatic insufficiency (Child-Pugh Class C): Reduce initial and target doses to 25% of normal dose 1

CYP2D6 Poor Metabolizers or Concurrent Strong CYP2D6 Inhibitors (paroxetine, fluoxetine, quinidine):

  • Children/adolescents under 70 kg: Start at 0.5 mg/kg/day, increase to 1.2 mg/kg/day only if symptoms fail to improve after 4 weeks and initial dose is well tolerated 1
  • Children/adolescents over 70 kg and adults: Start at 40 mg/day, increase to 80 mg/day only if symptoms fail to improve after 4 weeks and initial dose is well tolerated 1

Pre-Treatment Requirements

Baseline Assessment:

  • Obtain baseline blood pressure, pulse, height, and weight in the context of a physical examination 2
  • Screen for personal or family history of bipolar disorder, mania, or hypomania before initiating treatment 1
  • Document prior treatments including previous medications, dosages, duration, response, and side effects 2

Administration Considerations

Practical Points:

  • May be taken with or without food 1
  • Capsules must be swallowed whole; do not open 1
  • Can be discontinued without tapering 1
  • Single morning dose has been shown effective into the evening 3

Common Pitfalls to Avoid

Dose Escalation:

  • Avoid increasing the dose too rapidly, as this can cause initial somnolence and gastrointestinal symptoms 2
  • Always wait the minimum 3 days between dose increases 1

Safety Monitoring:

  • The safety of single doses over 120 mg and total daily doses above 150 mg have not been systematically evaluated 1
  • Monitor for suicidal ideation, particularly early in treatment, as atomoxetine carries a black-box warning for this risk 3
  • Rarely associated with serious liver injury; monitor for signs of hepatic dysfunction 3

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.